Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer

J Clin Gastroenterol. 2008 May-Jun;42(5):551-2. doi: 10.1097/MCG.0b013e31802da22e.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Female
  • Follow-Up Studies
  • Gemcitabine
  • Hemolytic-Uremic Syndrome / chemically induced*
  • Hemolytic-Uremic Syndrome / therapy
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Plasmapheresis
  • Ribonucleotide Reductases / antagonists & inhibitors

Substances

  • Immunosuppressive Agents
  • Deoxycytidine
  • Ribonucleotide Reductases
  • Gemcitabine